In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Malcolm Spicer

Malcolm Spicer, Managing Editor – US

Washington, DC
Malcolm Spicer is lead analyst for Pharma intelligence | informa's coverage of the consumer health care products industries. He provides comprehensive and insightful reporting on manufacturing, marketing, regulation, legislation, financial and research news about the nonprescription drug and nutritional product industries. He has worked in this post for 10 years and previously reported for other publications on regulation of the health care industry, on the telecommunications and internet technologies and on the US energy market.

Latest From Malcolm Spicer

Arizona Supplement Firm’s Problems Start With COVID-19 Claims, Reach SARMS, ED Drug

CDER notes in update to COVID-19 enforcement and other actions that Umbrella Labs made unlawful claims to prevent and treat the virus. Announcement didn’t note those claims weren’t first among violations identified in a warning letter to the firm.

Dietary Supplements FDA

Perrigo Expects Trans-Atlantic Boost: Eliminating Irish Tax Debt, Importing European Brands

In investor conference presentations, CEO Kessler says “we have a very strong case that the way we filed those taxes was correctly and the assessment should be 0,” and bringing its European consumer health brands to the US is “finally starting to really happen.”

OTC Drugs M & A

Progress On Adding OTC Drugs To US Market? Room To Move But Label Format Limits Options

Changes for supporting OTC labeling for drugs currently available Rx-only and indicated for chronic, more complicated conditions, aren’t minor and won’t happen within limits of one-dimensional text media printed on OTC drug containers, packages and inserts.

FDA OTC Drugs

‘Heretical’ Rule Changes Could Make More Drugs Available OTC In US – Former NDAC Chair Brass

Harbor-UCLA Center for Clinical Pharmacology director Eric Brass says FDA should change DFL requirements, considering container labels as part of OTC labeling and reconsidering what information should be included on labels and threshold for consumer comprehension of labels.

Drug Approval Standards FDA

UK Vibrating Device Marketer Unshaken By Regulatory Action Against COVID-19 Claims

Psychologist Anthony Grant operates “Resonator.UK” and sells a device that vibrates on the 30kHz frequency at 30,000 times a second. Claims including “the only safe way to destroy a virus is to shake it to pieces” challenged by MHRA and consumers.

Ad Complaints OTC Devices

Colgate Slams Industry Self-Regulation Review But Agrees To Pull Optic White Stain Removal Claim

BBB National Programs’ appeals panel decision “includes factual and substantive inaccuracies, is not in accordance with NARB procedures, and misstates Colgate’s positions and arguments,” Colgate says. Panel upheld findings agreeing with P&G’s challenge of “removes 10 years of yellow stains” claim.

Ad Complaints Commercial
See All
UsernamePublicRestriction

Register